Trial Profile
A study evaluating longer-term efficacy and safety of netazepide in patients with type 1 gastric neuroendocrine tumours
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2016
Price :
$35
*
At a glance
- Drugs Netazepide (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions; Therapeutic Use
- 05 Nov 2016 New trial record
- 04 Oct 2016 Results published in the British Journal of Clinical Pharmacology